Dominiak Monika, Gędek Adam, Sikorska Michalina, Mierzejewski Paweł, Wojnar Marcin, Antosik-Wójcińska Anna Z
Department of Pharmacology, Institute of Psychiatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland.
Praski Hospital, Aleja Solidarności 67, 03-401 Warsaw, Poland.
Pharmaceuticals (Basel). 2022 Dec 31;16(1):67. doi: 10.3390/ph16010067.
The effects of acetylsalicylic acid (ASA) on mood disorders (MD) and on inflammatory parameters in preclinical and clinical studies have not yet been comprehensively evaluated. The aim of this study was to systematically summarize the available knowledge on this topic according to PRISMA guidelines. Data from preclinical and clinical studies were analyzed, considering the safety and efficacy of ASA in the treatment of MD and the correlation of inflammatory parameters with the effect of ASA treatment. Twenty-one studies were included. Both preclinical and clinical studies found evidence indicating the safety and efficacy of low-dose ASA in the treatment of all types of affective episodes in MD. Observational studies have indicated a reduced risk of all types of affective episodes in chronic low-dose ASA users (HR 0.92, 95% CI: 0.88, 0.95, p < 0.0001). An association between ASA response and inflammatory parameters was found in preclinical studies, but this was not confirmed in clinical trials. Further long-term clinical trials evaluating the safety and efficacy of ASA in recurrent MD, as well as assessing the linkage of ASA treatment with inflammatory phenotype and cytokines, are required. There is also a need for preclinical studies to understand the exact mechanism of action of ASA in MD.
在临床前和临床研究中，乙酰水杨酸（ASA）对情绪障碍（MD）及炎症参数的影响尚未得到全面评估。本研究的目的是根据PRISMA指南系统总结关于该主题的现有知识。分析了临床前和临床研究的数据，考量了ASA治疗MD的安全性和有效性以及炎症参数与ASA治疗效果的相关性。共纳入21项研究。临床前和临床研究均发现有证据表明低剂量ASA治疗MD中所有类型情感发作具有安全性和有效性。观察性研究表明，慢性低剂量ASA使用者发生所有类型情感发作的风险降低（风险比0.92，95%置信区间：0.88，0.95，p<0.0001）。临床前研究发现了ASA反应与炎症参数之间的关联，但在临床试验中未得到证实。需要进一步开展长期临床试验，评估ASA在复发性MD中的安全性和有效性，并评估ASA治疗与炎症表型和细胞因子的联系。还需要进行临床前研究，以了解ASA在MD中的确切作用机制。
